Abstract:Epilepsy is a complex and multifaceted neurological disorder characterized by spontaneous and recurring seizures. It poses significant therapeutic challenges due to its diverse etiology and often-refractory nature. This comprehensive review highlights the pivotal role of AMP-activated protein kinase (AMPK), a key metabolic regulator involved in cellular energy homeostasis, which may be a promising therapeutic target for epilepsy. Current therapeutic strategies such as antiseizure medication (ASMs) can alleviate seizures (up to 70%). However, 30% of epileptic patients may develop refractory epilepsy. Due to the complicated nature of refractory epilepsy, other treatment options such as ketogenic dieting, adjunctive therapy, and in limited cases, surgical interventions are employed. These therapy options are only suitable for a select group of patients and have limitations of their own. Current treatment options for epilepsy need to be improved. Emerging evidence underscores a potential association between impaired AMPK functionality in the brain and the onset of epilepsy, prompting an in-depth examination of AMPK’s influence on neural excitability and ion channel regulation, both critical factors implicated in epileptic seizures. AMPK activation through agents such as metformin has shown promising antiepileptic effects in various preclinical and clinical settings. These effects are primarily mediated through the inhibition of the mTOR signaling pathway, activation of the AMPK-PI3K-c-Jun pathway, and stimulation of the PGC-1α pathway. Despite the potential of AMPK-targeted therapies, several aspects warrant further exploration, including the detailed mechanisms of AMPK’s role in different brain regions, the impact of AMPK under various conditional circumstances such as neural injury and zinc toxicity, the long-term safety and efficacy of chronic metformin use in epilepsy treatment, and the potential benefits of combination therapy involving AMPK activators. Moreover, the efficacy of AMPK activators in refractory epilepsy remains an open question. This review sets the stage for further research with the aim of enhancing our understanding of the role of AMPK in epilepsy, potentially leading to the development of more effective, AMPK-targeted therapeutic strategies for this challenging and debilitating disorder.

Pharmacological modulation of autophagy for epilepsy therapy: opportunities and obstacles

Intestinal Microbiota As an Alternative Therapeutic Target for Epilepsy

Insight into Drug Resistance in Status Epilepticus: Evidence from Animal Models

AMPK role in epilepsy: a promising therapeutic target?

Investigating the Effects of Perampanel on Autophagy-mediated Regulation of GluA2 and PSD95 in Epilepsy

Epigenetic regulation in epilepsy: A novel mechanism and therapeutic strategy for epilepsy

Interaction between electrical modulation of the brain and pharmacotherapy to control pharmacoresistant epilepsy

Epigenetic regulation of autophagy in neuroinflammation and synaptic plasticity

Lipid metabolism: Novel approaches for managing idiopathic epilepsy

New advances in pharmacoresistant epilepsy towards precise management-from prognosis to treatments

The Neurovascular Unit Dysfunction in the Molecular Mechanisms of Epileptogenesis and Targeted Therapy

Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy

Unraveling the Neural Circuits: Techniques, Opportunities and Challenges in Epilepsy Research

Metabotropic glutamate receptors (mGluRs) in epileptogenesis: an update on abnormal mGluRs signaling and its therapeutic implications

Microglia in epilepsy

Non-invasive Sensory Neuromodulation in Epilepsy: Updates and Future Perspectives

An update for epilepsy research and antiepileptic drug development: Toward precise circuit therapy

Role of DNA Methylation and Adenosine in Ketogenic Diet for Pharmacoresistant Epilepsy: Focus on Epileptogenesis and Associated Comorbidities

Pathogenesis, diagnosis, and treatment of epilepsy: electromagnetic stimulation–mediated neuromodulation therapy and new technologies

Role of the Mtor Signaling Pathway in Epilepsy

Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials